Table 2. Comparison of pathological characteristics between the two groups.

	APLA2R-ab (−) (N = 59)	APLA2R-ab (+) (N = 170)	P value
Pathological stage (%)
I	45/59 (76.27%)	112/170 (65.88%)	0.454
II	14/59 (23.72%)	55/170 (32.35%)	0.321
III + IV	0	2/170 (1.18%)	0.293
Tissue IgG	2.46 ± 0.83	2.37 ± 0. 89	0.486
Tissue IgM	0.36 ± 0.79	0.38 ± 0.69	0.810
Tissue IgA	0.12 ± 0.50	0.23 ± 0.61	0.182
Tissue C3	1.09 ± 0.87	1.19 ± 0.94	0.459
Tissue Fib	0.08 ± 0.39	0.15 ± 0.52	0.264
Tissue C1q	0.53 ± 0.80	0.50 ± 0.71	0.796
Pathological characteristics
Global sclerosis	35/59 (59.32%)	88/170 (51.76%)	0.337
Glomerular mesangial hyperplasia	16/59 (27.12%)	64/170 (37.65%)	0.124
Crescents	2/59 (3.38%)	0	0.159
Hyperplasia endothelialitis	4/59 (6.78%)	7/170 (4.12%)	0.418
Acute renal tubular lesions	2/59 (3.39%)	20/170 (11.76%)	0.015*
Chronic renal tubular lesions	2/59 (3.39%)	21/170 (13.53%)	0.010**
Inflammatory cell infiltration	3/59 (5.08%)	23/170 (13.53%)	0.031*
Vascular disease	21/59 (35.59%)	57/170 (33.53%)	0.796

Notes.

Compared with the PLa2R− group and the PLA2R+ group, P^∗ < 0.05, P^∗∗ < 0.01.